about
The core and accessory genomes of Burkholderia pseudomallei: implications for human melioidosisCelgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse modelThe re-emergence of dengue in ChinaNaturally acquired human Plasmodium knowlesi infection, SingaporeMutational dynamics of the SARS coronavirus in cell culture and human populations isolated in 2003Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever PatientsStructure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeFc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseasesDengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral SerotypesThe C-terminal 18 Amino Acid Region of Dengue Virus NS5 Regulates its Subcellular Localization and Contains a Conserved Arginine Residue Essential for Infectious Virus ProductionTuberculous meningitis is a major cause of mortality and morbidity in adults with central nervous system infections in Kota Kinabalu, Sabah, Malaysia: an observational studyCost-Effective Real-Time Reverse Transcriptase PCR (RT-PCR) To Screen for Dengue Virus followed by Rapid Single-Tube Multiplex RT-PCR for Serotyping of the VirusA Prospective Clinical Study on the Use of Reverse Transcription-Polymerase Chain Reaction for the Early Diagnosis of Dengue FeverDecision Tree Algorithms Predict the Diagnosis and Outcome of Dengue Fever in the Early Phase of IllnessGenomic Epidemiology of a Dengue Virus Epidemic in Urban SingaporeThe structural basis for serotype-specific neutralization of dengue virus by a human antibodyDengue: an update on treatment optionsThe early clinical features of dengue in adults: challenges for early clinical diagnosisSulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical applicationAnalysis of Dengue Virus Genetic Diversity during Human and Mosquito Infection Reveals Genetic ConstraintsProduction of Infectious Dengue Virus in Aedes aegypti Is Dependent on the Ubiquitin Proteasome PathwayProteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent InfectionSerum Metabolomics Reveals Serotonin as a Predictor of Severe Dengue in the Early Phase of Dengue FeverIn vitro inhibition of human influenza A virus replication by chloroquine.Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in miceSafety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library.A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic.Economic analysis of pandemic influenza vaccination strategies in Singapore.An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice.Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice.Patterns of medication use and factors associated with antibiotic use among adult fever patients at Singapore primary care clinics.Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial.A simple and powerful method for the estimation of intervention effects on serological endpoints using paired interval-censored data.Dengue virus compartmentalization during antibody-enhanced infection.Dengue virus activates cGAS through the release of mitochondrial DNAFirst experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodiesThe 5' and 3' Untranslated Regions of the Flaviviral Genome.Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1.Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice.
P50
Q21131589-7C08975D-6A00-4FF3-B2B0-2D968FC40108Q24276104-EFDA36BA-2665-48C0-A26C-3A385ED0CE9AQ24288878-5358C5A1-9F92-46C9-A45F-3255ABA10B1EQ24646977-330CF337-15CA-4C64-AB93-3CEA77F9FA41Q24792415-81BDD907-AD38-4866-BD15-A11B2642D4BBQ26257542-17D19D26-CAD9-485F-8EE4-75AEE9F8BF78Q26700120-4B236046-A648-4850-9EEA-08D9498484DFQ26783175-DBEF7282-2D81-4BE0-9581-3E23F6C65C07Q27304342-6B78B0F7-4F14-4947-A3F3-82EE770AF906Q27468720-D791782E-EE85-4881-A06C-5F16281DB0E7Q27469054-98F2B55B-96D2-4A24-9552-A2A80AD0B4CDQ27478185-B3449FEB-3C01-419E-B0C6-6A72ED9647A9Q27478418-C6A221B0-A43A-4FE2-BEAF-E7239CE5536CQ27485469-DBCB9FF0-AC64-4619-A9FA-41ED10931D14Q27488304-16C8D703-E548-4E48-8F2F-3928EDE56952Q27681306-612E1FE7-030F-49E1-BB18-BAAD8E95D611Q28085044-EDC26CEC-581F-49B3-8481-1D0E835AD651Q28478345-C909A748-11F7-4B43-A7E5-7B1CCDCD1AB3Q28486916-8CA8EA18-4D7E-4BBF-BCCF-D67658DB66D7Q28547668-02B92296-7678-4934-9F5B-2987BA86BE9CQ28550947-F76A868D-37A3-4757-8624-E8EF84E5E9EEQ28550953-F08AC072-EE71-4AD4-8724-3428052416ABQ28551236-4E94D256-46E3-43AA-9774-0581C8F8928EQ30230591-034FDB7F-DEAF-466F-AFB5-C9180F2142DEQ30357432-0C170464-4A4E-4B87-851F-8E130563867DQ30364932-78D1727C-EB74-4D42-A415-83A84621121EQ30372987-B4DD001C-2E92-4A55-9F07-0C3E99C77C35Q30374413-34067CEA-9B8E-4259-8234-5D22BC7736B8Q30380974-09F71966-2132-4956-BBB3-8CA122FB629DQ30390234-D68C97DC-CB1E-4B1A-B7BB-BA3028CF21FEQ30391956-581DB050-168E-4C00-AC98-755ED9320B0EQ30395845-60E34E69-A7F0-470E-952A-3080027838DCQ30402402-A96DEAAE-1F7C-4C5B-BEEF-E69894C7E54DQ30822715-0992ACF8-53BB-4BBA-9915-235CA044439BQ30834861-D445D28C-C8CD-4720-9530-0BA07B38C9F2Q30855840-D2BB1E95-C659-46B7-A918-497962942E94Q31156754-98935211-124D-4BC5-ACD3-69223C0B751BQ32183359-FD9F24E5-8846-455A-805C-4F2816728688Q33350700-3092131A-A6E1-4772-AA42-516D6E8F5C4FQ33409934-516DE5A1-34DB-473D-B667-A77247A22568
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eng Eong Ooi
@ast
Eng Eong Ooi
@en
Eng Eong Ooi
@es
Eng Eong Ooi
@nl
Eng Eong Ooi
@sl
type
label
Eng Eong Ooi
@ast
Eng Eong Ooi
@en
Eng Eong Ooi
@es
Eng Eong Ooi
@nl
Eng Eong Ooi
@sl
prefLabel
Eng Eong Ooi
@ast
Eng Eong Ooi
@en
Eng Eong Ooi
@es
Eng Eong Ooi
@nl
Eng Eong Ooi
@sl
P1006
P214
P244
P1006
P106
P1153
7004519587
P214
P244
no2003055771
P31
P496
0000-0002-0520-1544
P7859
lccn-no2003055771